Tango leverages high-throughput CRISPR screening to identify vulnerabilities in cancer cells. The firm focuses on diseases with high unmet need where patients share a common genetic context. Tango says it is committed to developing precise, powerful and safe therapies for the people who need them most.

In April 2021, Tango signed a deal with BCTG Acquisition, a special-purpose acquisition company, or SPAC, sponsored by San Diego's Boxer Capital, to go public through a reverse merger.